Inquiry Basket
CAS No.:
Cat No.: BADC-00741
4.5 
MA-PEG8-VA-PAB-SG3199 is a drug-linker conjugate for ADC by using SG3199 (a PBD dimer,has a potently cytotoxic against cancer cell lines), linked via MA-PEG8-VA-PAB.
Structure of
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
MA-PEG8-VA-PAB-SG3199, a sophisticated chemical linker molecule, plays a pivotal role in drug development and molecular engineering.
Antibody-Drug Conjugates (ADCs): Serving as a critical linker in ADC development, MA-PEG8-VA-PAB-SG3199 is instrumental in crafting targeted cancer therapies that fuse monoclonal antibodies with cytotoxic drugs. This linker enables the secure attachment of the drug to the antibody, orchestrating a controlled release within cancer cells. It delicately balances stability in circulation with swift release in the tumor microenvironment, enhancing treatment efficacy while mitigating adverse effects.
Controlled-Release Systems: Leveraging the unique chemical properties of MA-PEG8-VA-PAB-SG3199, advanced controlled-release drug delivery systems come to fruition. By incorporating this linker into drug formulations, a prolonged and regulated release of therapeutic agents is achieved. Particularly advantageous for drugs with narrow therapeutic windows, it reduces dosing frequency and enhances patient adherence.
Bioconjugation Studies: Unveiling its versatility, MA-PEG8-VA-PAB-SG3199 emerges as a pivotal tool in bioconjugation methodologies, essential for coupling biomolecules in the study and elucidation of proteins, peptides, and small molecules. Researchers harness this linker to unravel the intricate interactions between diverse biological entities, nurturing the evolution of novel diagnostic assays and therapeutic agents.
Tumor Microenvironment Targeting: Shedding light on cancer research, MA-PEG8-VA-PAB-SG3199 empowers the engineering of drug molecules tailored to target the tumor microenvironment. By fine-tuning its incorporation, novel drug formulations can selectively target specific enzymes or conditions unique to tumor tissues, orchestrating a precise release of therapeutics. This targeted approach enhances the precision of cancer therapies, ensuring minimal harm to healthy tissues while maximizing impact on tumors, reshaping the paradigm of oncological treatment strategies.
| Catalog | Product Name | CAS | Inquiry |
|---|---|---|---|
| BADC-01353 | SG3199 | 1595275-71-0 | |
| BADC-01345 | MC-Val-Ala-SG3199 | ||
| BADC-00766 | DBCO-PEG8-VA-PAB-SG3199 |
What is MA-PEG8-VA-PAB-SG3199?
MA-PEG8-VA-PAB-SG3199 is a DNA-alkylating payload designed for ADCs, featuring a maleimide (MA) conjugation site, PEG8 solubilizer, valine-alanine (VA) dipeptide linker, and PAB self-immolative spacer coupled to the SG3199 cytotoxic agent.
20/2/2019
We are interested in how MA-PEG8-VA-PAB-SG3199 releases SG3199.
The VA linker is cleaved by lysosomal proteases upon internalization, initiating self-immolation of the PAB spacer and releasing the SG3199 agent for DNA cross-linking and cytotoxicity within target cells.
27/8/2018
Could you advise what advantages PEG8 provides in this payload?
PEG8 enhances solubility and reduces aggregation of the ADC, improving pharmacokinetics and allowing higher drug-to-antibody ratios, while maintaining stability during systemic circulation.
6/9/2022
Good morning! Could you explain how MA-PEG8-VA-PAB-SG3199 is conjugated to antibodies?
The maleimide group reacts with thiol residues on antibody cysteines, forming stable thioether linkages. This ensures precise conjugation, preserving antibody binding and allowing controlled payload delivery.
26/8/2018
Good afternoon! Could you advise what research applications are supported by MA-PEG8-VA-PAB-SG3199?
It is used in preclinical ADC development to assess cytotoxicity, evaluate linker-payload efficiency, and optimize pharmacokinetics and targeted delivery in oncology research.
12/8/2021
— Dr. Julia Martin, ADC Research Scientist (USA)
MA-PEG8-VA-PAB-SG3199 linker offered high stability and efficient conjugation, supporting our ADC research.
6/9/2022
— Mr. Erik Johansson, Medicinal Chemist (Sweden)
Excellent purity and reproducibility of MA-PEG8-VA-PAB-SG3199 enabled consistent DAR outcomes.
12/8/2021
— Dr. Maria Rossi, Biochemistry Specialist (Italy)
The linker integrated seamlessly into our workflow with minimal by-products.
26/8/2018
— Prof. John Miller, Pharmaceutical Chemistry (UK)
High-quality MA-PEG8-VA-PAB-SG3199 supported reliable preclinical ADC studies.
20/2/2019
— Dr. Emma Schneider, Senior Researcher (Germany)
Consistently high purity and solubility made this linker ideal for our conjugation experiments.
— Mr. David Clark, Conjugation Specialist (USA)
Smooth ADC assembly and predictable reaction profile using MA-PEG8-VA-PAB-SG3199.
27/8/2018
MA-PEG8-VA-PAB-SG3199
Required fields are marked with *
MA-PEG8-VA-PAB-SG3199
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
